Terms: = Endocrine gland cancer AND HER1, YOR227W
45 results:
1. Recent advances in the development of EGFR degraders: PROTACs and LYTACs.
Hong D; Zhou B; Zhang B; Ren H; Zhu L; Zheng G; Ge M; Ge J
Eur J Med Chem; 2022 Sep; 239():114533. PubMed ID: 35728507
[TBL] [Abstract] [Full Text] [Related]
2. NRF2 Regulates her1 Signaling Pathway to Modulate the Sensitivity of Ovarian cancer Cells to Lapatinib and Erlotinib.
Kankia IH; Khalil HS; Langdon SP; Moult PR; Bown JL; Deeni YY
Oxid Med Cell Longev; 2017; 2017():1864578. PubMed ID: 29410730
[TBL] [Abstract] [Full Text] [Related]
3. Development of epidermal growth factor receptor targeted therapy in pancreatic cancer.
Qing L; Qing W
Minerva Chir; 2018 Oct; 73(5):488-496. PubMed ID: 29397631
[TBL] [Abstract] [Full Text] [Related]
4. The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer : her1-4 protein expression and prognosis in pancreatic cancer.
Li Q; Zhang L; Li X; Yan H; Yang L; Li Y; Li T; Wang J; Cao B
BMC Cancer; 2016 Nov; 16(1):910. PubMed ID: 27871278
[TBL] [Abstract] [Full Text] [Related]
5. Targeting peptidyl-prolyl isomerase pin1 to inhibit tumor cell aggressiveness.
Beretta GL; De Cesare M; Albano L; Magnifico A; Carenini N; Corna E; Perego P; Gatti L
Tumori; 2016; 102(2):144-9. PubMed ID: 26917410
[TBL] [Abstract] [Full Text] [Related]
6. Profiling of cMET and HER Family Receptor Expression in Pancreatic Ductal Adenocarcinomas and Corresponding Lymph Node Metastasis to Assess Relevant Pathways for Targeted Therapies: Looking at the Soil Before Planting the Seed.
Muckenhuber A; Babitzki G; Thomas M; Hölzlwimmer G; Zajac M; Jesinghaus M; Bergmann F; Werner J; Stenzinger A; Weichert W
Pancreas; 2016 Sep; 45(8):1167-74. PubMed ID: 26825865
[TBL] [Abstract] [Full Text] [Related]
7. An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Wang Z; Fu S
Expert Opin Investig Drugs; 2016; 25(1):15-30. PubMed ID: 26560712
[TBL] [Abstract] [Full Text] [Related]
8. In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography.
Nielsen CH; Jensen MM; Kristensen LK; Dahlman A; Fröhlich C; Jacobsen HJ; Poulsen TT; Lantto J; Horak ID; Kragh M; Kjaer A
Oncotarget; 2015 Nov; 6(35):37486-99. PubMed ID: 26460961
[TBL] [Abstract] [Full Text] [Related]
9. Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic cancer Cells.
Lee S; Heinrich EL; Lu J; Lee W; Choi AH; Luu C; Chung V; Fakih M; Kim J
Pancreas; 2016 Feb; 45(2):286-92. PubMed ID: 26262587
[TBL] [Abstract] [Full Text] [Related]
10. HER family receptor expression and prognosis in pancreatic cancer.
Bittoni A; Mandolesi A; Andrikou K; Santoni M; Alfonsi S; Lanese A; Loretelli C; Pellei C; Piva F; Scarpelli M; Cascinu S
Int J Biol Markers; 2015 Jul; 30(3):e327-32. PubMed ID: 26109364
[TBL] [Abstract] [Full Text] [Related]
11. Dual targeting of her1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial.
Assenat E; Azria D; Mollevi C; Guimbaud R; Tubiana-Mathieu N; Smith D; Delord JP; Samalin E; Portales F; Larbouret C; Robert B; Bibeau F; Bleuse JP; Crapez E; Ychou M; Pèlegrin A
Oncotarget; 2015 May; 6(14):12796-808. PubMed ID: 25918250
[TBL] [Abstract] [Full Text] [Related]
12. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer.
Pettazzoni P; Viale A; Shah P; Carugo A; Ying H; Wang H; Genovese G; Seth S; Minelli R; Green T; Huang-Hobbs E; Corti D; Sanchez N; Nezi L; Marchesini M; Kapoor A; Yao W; Francesco ME; Petrocchi A; Deem AK; Scott K; Colla S; Mills GB; Fleming JB; Heffernan TP; Jones P; Toniatti C; DePinho RA; Draetta GF
Cancer Res; 2015 Mar; 75(6):1091-101. PubMed ID: 25736685
[TBL] [Abstract] [Full Text] [Related]
13. Evaluation of the dimerization profiles of HER tyrosine kinases by time-resolved Förster resonance energy transfer (TR-FRET).
Lopez-Crapez E; Ho-Pun-Cheung A; Garnero P; Bazin H
Methods Mol Biol; 2015; 1233():45-55. PubMed ID: 25319888
[TBL] [Abstract] [Full Text] [Related]
14. Molecular recognition of HER-1 in whole-blood samples.
Moldoveanu I; Stanciu Gavan C; Stefan-van Staden RI
J Mol Recognit; 2014 Nov; 27(11):653-8. PubMed ID: 25277089
[TBL] [Abstract] [Full Text] [Related]
15. Heparin-binding EGF-like growth factor enhances the activity of invasion and metastasis in thyroid cancer cells.
Ota I; Higashiyama S; Masui T; Yane K; Hosoi H; Matsuura N
Oncol Rep; 2013 Oct; 30(4):1593-600. PubMed ID: 23917679
[TBL] [Abstract] [Full Text] [Related]
16. The use of fluorescent proteins for developing cancer-specific target imaging probes.
McCann TE; Kosaka N; Choyke PL; Kobayashi H
Methods Mol Biol; 2012; 872():191-204. PubMed ID: 22700412
[TBL] [Abstract] [Full Text] [Related]
17. Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation.
Luedke E; Jaime-Ramirez AC; Bhave N; Carson WE
J Immunother; 2012 Jun; 35(5):367-73. PubMed ID: 22576341
[TBL] [Abstract] [Full Text] [Related]
18. Alterations in c-Src/her1 and estrogen receptor α signaling pathways in mammary gland and tumors of hexachlorobenzene-treated rats.
Peña D; Pontillo C; García MA; Cocca C; Alvarez L; Chiappini F; Bourguignon N; Frahm I; Bergoc R; Kleiman de Pisarev D; Randi A
Toxicology; 2012 Mar; 293(1-3):68-77. PubMed ID: 22245120
[TBL] [Abstract] [Full Text] [Related]
19. Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors.
Albini A; Cesana E; Donatelli F; Cammarota R; Bucci EO; Baravelli M; Anzà C; Noonan DM
Future Cardiol; 2011 Sep; 7(5):693-704. PubMed ID: 21929348
[TBL] [Abstract] [Full Text] [Related]
20. Vandetanib: first global approval.
Commander H; Whiteside G; Perry C
Drugs; 2011 Jul; 71(10):1355-65. PubMed ID: 21770481
[TBL] [Abstract] [Full Text] [Related]
[Next]